Table 1 Patient and disease characteristics at baseline

From: Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer

Characteristic

Number of patients ( N =40)

%

Sex

  

 Male

30

75.0

 Female

10

25.0

Age, years

  

 Median

55

 

 Range

33–74

 

Performance status (ECOG)

  

 0

7

17.5

 1

29

72.5

 2

4

10.0

Disease status

  

 Relapsed

5

12.5

 Adjuvant chemotherapy

3

 

 No adjuvant chemotherapy

2

 

 Initially metastatic

35

87.5

Location

  

 Proximal

5

12.5

 Middle

4

10.0

 Distal

26

65.0

 Diffuse

5

12.5

Lauren classification

  

 Intestinal

12

30.0

 Diffuse

28

70.0

Number of organs involved

  

 1

5

12.5

 2

7

17.5

 3

17

42.5

 4

7

17.5

5

4

10.0

Site of metastasis

  

 Lymph node

36

90.0

 Peritoneum

21

52.5

 Liver

16

40.0

 Others (lung, bone, and so on)

9

22.5

  1. ECOG, Eastern Cooperative Oncology Group.